Researchers conducted this study to determine whether bone bridge formation was correlated with low bone mineral density in patients with ankylosing spondylitis.
Researchers assessed serum levels of osteogenic factors and the different regulators of bone formation in patients with early axial spondyloarthritis.
Patients with greater BMD improvement after 1 year of denosumab are more likely to lose BMD after the transition to alendronate therapy in the second year.
The study, presented at the American Society for Bone and Mineral Research 2019 Annual Meeting, described the experience of patients who initiated treatment with abaloparatide.
Researchers investigated the safety and efficacy of twice-weekly 28.2 μg teriparatide compared with once-weekly 56.5 μg teriparatide in Japanese patients with osteoporosis.
Researchers investigated the case of a patient with sclerosing osteomyelitis who was successfully treated with zoledronic acid.